Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
about
Surgical technology and pharmacology of hyperthermic perioperative chemotherapyLooking up: Recent advances in understanding and treating peritoneal carcinomatosisTumor infiltrating lymphocytes in ovarian cancerPrognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysisRisk of ischemic stroke in patients with ovarian cancer: a nationwide population-based study.Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancerThe prognostic value of CXCR4 in ovarian cancer: a meta-analysisPrognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.Characteristics of Long-Term Survivors of Epithelial Ovarian CancerUse and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerAssociation of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian CarcinomaOvarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions.Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancerHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer.Taxanes: their impact on gynecologic malignancy.Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality.The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study.Long non-coding RNA SOX2OT promotes cell proliferation and motility in human ovarian cancer.Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectivesHeated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian CancerAltered long noncoding RNAs and survival outcomes in ovarian cancer: A systematic review and meta-analysis (PRISMA Compliant)Update on the management of malignant peritoneal mesothelioma
P2860
Q26768405-42F7381B-6EFA-4B03-A9EE-91490BD8C929Q26849259-B10CCEDD-82DC-4AFD-B8A2-A3ACDD5376ECQ27021878-F1370A14-3BFA-4F18-AB35-7F0C6929A86EQ27027801-F85B641D-FAF3-42C1-ABED-EC426A5B7F2AQ33616584-5CFB054D-E914-4F37-877B-54E5491565B2Q33816983-A0CE9533-9329-4BAD-BAEC-82DD46B6E135Q35064627-39D9BD27-103B-421F-8C09-D20BA29D1220Q35127922-BFD17428-5C86-427C-9023-C17D179E2C02Q35533363-10F1C8C2-9BA6-4E6B-A79D-DF2E876B819FQ35984294-14E0D53C-57B6-476C-93C8-F6A0BCDBD21AQ36011137-B61DEE14-FC47-4505-A103-ADFA924C056FQ36170289-5EC522B0-2AFA-402F-8884-51009E684EBDQ36433053-9FDCFEB9-F9BD-437E-AF72-2F78C231D6ADQ36494695-5B53B707-8738-4193-9BF3-2DAED6BDEF53Q36588670-7CAB50C0-5739-44D2-9041-63513D11AAFCQ36884415-51AECCD6-D987-449A-B595-26DAD57BE5ABQ37029841-4DD63787-2A7A-434E-BCD8-F37E6F5D3185Q37430771-0F438FC4-7995-470E-B87A-B4BD48289436Q37684614-F520E65A-0C21-4BFD-9F9C-BD895324415AQ37692801-5CCAD9E5-4606-478F-B051-91A2084B4BA5Q38171356-C202775B-F137-4979-93CA-089F89F02AB0Q38243089-5F394231-70CA-48AB-B9CA-10506154F1B1Q38635932-075D591E-F14C-4727-BF28-30AEB83370DAQ43114850-2CDA7AE6-BD1E-4EAD-81EE-76EB21D2F4D0Q43883988-5184F9E4-0512-47EE-B8D8-E79CCC797B43Q48830395-F7B307AC-53DB-4CAE-B1F2-58CC7EAB69E1Q49399386-BE9DC694-A0AB-4982-BA81-0E80E97724E1Q52941950-237DE865-1CBF-4F51-9046-3BC66E13991DQ58541846-F38BAFD4-D9A8-41AE-B6BA-781C6E3DFEDAQ58773636-B2819384-52B7-4F58-A646-C6E411A13385Q58789108-7007C487-F771-4B32-B149-39A1274130EBQ59132466-ECEE4E25-EF97-4316-99DB-A45B10592DE8
P2860
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prognostic factors for stage I ...... ecologic Oncology Group study.
@ast
Prognostic factors for stage I ...... ecologic Oncology Group study.
@en
type
label
Prognostic factors for stage I ...... ecologic Oncology Group study.
@ast
Prognostic factors for stage I ...... ecologic Oncology Group study.
@en
prefLabel
Prognostic factors for stage I ...... ecologic Oncology Group study.
@ast
Prognostic factors for stage I ...... ecologic Oncology Group study.
@en
P2093
P2860
P1433
P1476
Prognostic factors for stage I ...... ecologic Oncology Group study.
@en
P2093
Deborah K Armstrong
Grainger S Lanneau
James Java
Joan L Walker
Larry J Copeland
Lisa M Landrum
P2860
P356
10.1016/J.YGYNO.2013.04.001
P407
P50
P577
2013-04-08T00:00:00Z